Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment

BACKGROUND/AIMS: Adalimumab dose escalation is one of the most important options in refractory Crohn's disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn's disease patients with loss of respo...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Case Rep Gastroenterol
Auteurs principaux: Suzuki, Taketo, Mizoshita, Tsutomu, Sugiyama, Tomoya, Hirata, Yoshikazu, Kimura, Yoshihide, Suzuki, Yuka, Yamada, Tomonori, Tsukamoto, Hironobu, Mizushima, Takashi, Sugimura, Naomi, Katano, Takahito, Tanida, Satoshi, Kataoka, Hiromi, Sasaki, Makoto
Format: Artigo
Langue:Inglês
Publié: S. Karger AG 2019
Sujets:
Case Series
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6547276/
https://ncbi.nlm.nih.gov/pubmed/31182942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000496453
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires